NCT02029001
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations:
Breast Cancer Tissue:
Recruitment Status: Recruiting
Phase 2
Drug Category: Tyrosine-Kinase Inhibitor, Serine-Threonine Kinase Inhibitor
Key Eligibility Criteria:
Gender: All
Age: 18 Years and older (Adult), Senior)
Location of Metastases:
Additional Notes:
Exclusions: Any patient NOT affiliated to the French social security system
https://ClinicalTrials.gov/show/NCT02029001